These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17989779)

  • 41. Compliance with antimicrobial therapy for buruli ulcer.
    Klis S; Kingma R; Tuah W; Stienstra Y; van der Werf TS
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6340. PubMed ID: 25225342
    [No Abstract]   [Full Text] [Related]  

  • 42. Reply to "compliance with antimicrobial therapy for buruli ulcer".
    Phillips RO; Sarfo FS; Abass MK; Frimpong M; Ampadu E; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6341. PubMed ID: 25225343
    [No Abstract]   [Full Text] [Related]  

  • 43.
    Kwofie SK; Dankwa B; Odame EA; Agamah FE; Doe LPA; Teye J; Agyapong O; Miller WA; Mosi L; Wilson MD
    Molecules; 2018 Jun; 23(7):. PubMed ID: 29954088
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [A Papua New Guinean with three foot ulcers].
    Coenders A; Verregghen M; Baerends EP
    Ned Tijdschr Geneeskd; 2018; 162():D2295. PubMed ID: 29372678
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impacts of dosing frequency of the combination rifampin-streptomycin on its bactericidal and sterilizing activities against Mycobacterium ulcerans in mice.
    Ji B; Chauffour A; Aubry A; Robert J; Ibrahim M; Jarlier V
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2955-9. PubMed ID: 19364857
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunohistochemical monitoring of wound healing in antibiotic treated Buruli ulcer patients.
    Andreoli A; Ruf MT; Sopoh GE; Schmid P; Pluschke G
    PLoS Negl Trop Dis; 2014 Apr; 8(4):e2809. PubMed ID: 24762629
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease.
    Sarfo FS; Phillips RO; Zhang J; Abass MK; Abotsi J; Amoako YA; Adu-Sarkodie Y; Robinson C; Wansbrough-Jones MH
    BMC Infect Dis; 2014 Apr; 14():202. PubMed ID: 24731247
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Buruli ulcer treatment: Rate of surgical intervention differs highly between treatment centers in West Africa.
    Wadagni AC; Steinhorst J; Barogui YT; Catraye PM; Gnimavo R; Abass KM; Amofa G; Frimpong M; Sarpong FN; van der Werf TS; Phillips R; Sopoh GE; Johnson CR; Stienstra Y
    PLoS Negl Trop Dis; 2019 Oct; 13(10):e0007866. PubMed ID: 31658295
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Providing insight into the incubation period of Mycobacterium ulcerans disease: two case reports.
    Amoako YA; Frimpong M; Awuah DO; Plange-Rhule G; Boakye-Yiadom E; Agbavor B; Sarpong F; Ahor H; Adu E; Danso KG; Abass MK; Asiedu K; Wansbrough-Jones M; Phillips RO
    J Med Case Rep; 2019 Jul; 13(1):218. PubMed ID: 31315637
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin.
    Johnson RC; Sáez-López E; Anagonou ES; Kpoton GG; Ayelo AG; Gnimavo RS; Mignanwande FZ; Houezo JG; Sopoh GE; Addo J; Orford L; Vlasakakis G; Biswas N; Calderon F; Della Pasqua O; Gine-March A; Herrador Z; Mendoza-Losana A; Díez G; Cruz I; Ramón-García S
    Trials; 2022 Jul; 23(1):559. PubMed ID: 35804454
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.
    Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exploration of a standard treatment for Buruli ulcer through a comprehensive analysis of all cases diagnosed in Japan.
    Sugawara M; Ishii N; Nakanaga K; Suzuki K; Umebayashi Y; Makigami K; Aihara M
    J Dermatol; 2015 Jun; 42(6):588-95. PubMed ID: 25809502
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacologic management of
    Van Der Werf TS; Barogui YT; Converse PJ; Phillips RO; Stienstra Y
    Expert Rev Clin Pharmacol; 2020 Apr; 13(4):391-401. PubMed ID: 32310683
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Amoebae as potential environmental hosts for Mycobacterium ulcerans and other mycobacteria, but doubtful actors in Buruli ulcer epidemiology.
    Gryseels S; Amissah D; Durnez L; Vandelannoote K; Leirs H; De Jonckheere J; Silva MT; Portaels F; Ablordey A; Eddyani M
    PLoS Negl Trop Dis; 2012; 6(8):e1764. PubMed ID: 22880141
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer.
    Silva MT; Portaels F; Pedrosa J
    Lancet Infect Dis; 2009 Nov; 9(11):699-710. PubMed ID: 19850228
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Surgical management of buruli ulcer disease: a four-year experience from four endemic districts in ghana.
    Adu E; Ampadu E; Acheampong D
    Ghana Med J; 2011 Mar; 45(1):4-9. PubMed ID: 21572818
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Histological and quantitative polymerase chain reaction-based analysis of Buruli ulcer using mapping biopsy method.
    Takahashi T; Kabuto M; Nakanishi G; Tanaka T; Fujimoto N
    PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008051. PubMed ID: 32569298
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Child case of Buruli ulcer successfully treated through a school-based skin survey project in Côte d'Ivoire.
    Yotsu RR; Murase C; N'guessan K; Yao A; Kouadio K; N'Golo DC; N'Guetta A; Akiyama M; Constance K; Vagamon B
    J Dermatol; 2020 Feb; 47(2):e64-e65. PubMed ID: 31729074
    [No Abstract]   [Full Text] [Related]  

  • 59. Efficacy of an Acid-Oxidizing Solution against Mycobacterium ulcerans.
    Warryn L; Pluschke G
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0087021. PubMed ID: 34662181
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Challenges associated with the treatment of Buruli ulcer.
    Aboagye SY; Kpeli G; Tuffour J; Yeboah-Manu D
    J Leukoc Biol; 2019 Feb; 105(2):233-242. PubMed ID: 30168876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.